The Splicing Factor RBM4 Controls Apoptosis, Proliferation, and Migration to Suppress Tumor Progression

Cancer Cell

Volumn 26, Issue 3, 2014, Pages 374-389

  Wang, Yang ^a,b   Chen, Dan ^a   Qian, Haili ^c   Tsai, YihsuanS ^b   Shao, Shujuan ^a   Liu, Quentin ^a   Dominguez, Daniel ^b   Wang, Zefeng ^b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BCL X; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN; MTOR PROTEIN, HUMAN; NUCLEAR PROTEIN; RBM4 PROTEIN, HUMAN; RNA BINDING PROTEIN; SERINE ARGININE RICH SPLICING PROTEINS; SERINE-ARGININE-RICH SPLICING PROTEINS; TARGET OF RAPAMYCIN KINASE;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE CONTROL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; CANCER TRANSPLANTATION; CELL MOTION; DISEASE COURSE; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MORTALITY; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ALTERNATIVE SPLICING; ANIMALS; APOPTOSIS; BASE SEQUENCE; BCL-X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; RNA-BINDING PROTEINS; TOR SERINE-THREONINE KINASES; TRANSCRIPTOME; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEINS;

EID: 84908686543     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.07.010     Document Type: Article

References (49)

1. Adams J.M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337.
2. Anczuków O., Rosenberg A.Z., Akerman M., Das S., Zhan L., Karni R., Muthuswamy S.K., Krainer A.R. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat. Struct. Mol. Biol. 2012, 19:220-228.
3. Bauman J.A., Li S.D., Yang A., Huang L., Kole R. Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res. 2010, 38:8348-8356.
4. Bechara E.G., Sebestyén E., Bernardis I., Eyras E., Valcárcel J. RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol. Cell 2013, 52:720-733.
5. Ben-Hur V., Denichenko P., Siegfried Z., Maimon A., Krainer A., Davidson B., Karni R. S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Reports 2013, 3:103-115.
6. Blaustein M., Pelisch F., Tanos T., Muñoz M.J., Wengier D., Quadrana L., Sanford J.R., Muschietti J.P., Kornblihtt A.R., Cáceres J.F., et al. Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nat. Struct. Mol. Biol. 2005, 12:1037-1044.
7. Brown R.L., Reinke L.M., Damerow M.S., Perez D., Chodosh L.A., Yang J., Cheng C. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J. Clin. Invest. 2011, 121:1064-1074.
8. Buchholz M., Braun M., Heidenblut A., Kestler H.A., Klöppel G., Schmiegel W., Hahn S.A., Lüttges J., Gress T.M. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 2005, 24:6626-6636.
9. Choudhury R., Roy S.G., Tsai Y.S., Tripathy A., Graves L.M., Wang Z. The splicing activator DAZAP1 integrates splicing control into MEK/Erk-regulated cell proliferation and migration. Nat. Commun. 2014, 5:3078.
10. Danial N.N. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin. Cancer Res. 2007, 13:7254-7263.
11. David C.J., Manley J.L. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 2010, 24:2343-2364.
12. Dehm S.M. mRNA splicing variants: exploiting modularity to outwit cancer therapy. Cancer Res. 2013, 73:5309-5314.
13. Del Gatto-Konczak F., Olive M., Gesnel M.C., Breathnach R. hnRNP A1 recruited to an exon invivo can function as an exon splicing silencer. Mol. Cell. Biol. 1999, 19:251-260.
14. Erkelenz S., Mueller W.F., Evans M.S., Busch A., Schöneweis K., Hertel K.J., Schaal H. Position-dependent splicing activation and repression by SR and hnRNP proteins rely on common mechanisms. RNA 2013, 19:96-102.
15. Fairbrother W.G., Yeh R.F., Sharp P.A., Burge C.B. Predictive identification of exonic splicing enhancers in human genes. Science 2002, 297:1007-1013.
16. Finak G., Bertos N., Pepin F., Sadekova S., Souleimanova M., Zhao H., Chen H., Omeroglu G., Meterissian S., Omeroglu A., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 2008, 14:518-527.
17. Ghigna C., Valacca C., Biamonti G. Alternative splicing and tumor progression. Curr. Genomics 2008, 9:556-570.
18. Graveley B.R., Maniatis T. Arginine/serine-rich domains of SR proteins can function as activators of pre-mRNA splicing. Mol. Cell 1998, 1:765-771.
19. Gyorffy B., Lánczky A., Szállási Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr. Relat. Cancer 2012, 19:197-208.
20. Kar A., Havlioglu N., Tarn W.Y., Wu J.Y. RBM4 interacts with an intronic element and stimulates tau exon 10 inclusion. J. Biol. Chem. 2006, 281:24479-24488.
21. Karni R., de Stanchina E., Lowe S.W., Sinha R., Mu D., Krainer A.R. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 2007, 14:185-193.
22. Karni R., Hippo Y., Lowe S.W., Krainer A.R. The splicing-factor oncoprotein SF2/ASF activates mTORC1. Proc. Natl. Acad. Sci. USA 2008, 105:15323-15327.
23. Lai M.C., Kuo H.W., Chang W.C., Tarn W.Y. A novel splicing regulator shares a nuclear import pathway with SR proteins. EMBO J. 2003, 22:1359-1369.
24. Lessene G., Czabotar P.E., Sleebs B.E., Zobel K., Lowes K.N., Adams J.M., Baell J.B., Colman P.M., Deshayes K., Fairbrother W.J., et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat. Chem. Biol. 2013, 9:390-397.
25. Lin J.C., Tarn W.Y. Exon selection in alpha-tropomyosin mRNA is regulated by the antagonistic action of RBM4 and PTB. Mol. Cell. Biol. 2005, 25:10111-10121.
26. Lin J.C., Tarn W.Y. RNA-binding motif protein 4 translocates to cytoplasmic granules and suppresses translation via argonaute2 during muscle cell differentiation. J. Biol. Chem. 2009, 284:34658-34665.
27. Lin J.C., Hsu M., Tarn W.Y. Cell stress modulates the function of splicing regulatory protein RBM4 in translation control. Proc. Natl. Acad. Sci. USA 2007, 104:2235-2240.
28. Lin J.C., Yan Y.T., Hsieh W.K., Peng P.J., Su C.H., Tarn W.Y. RBM4 promotes pancreas cell differentiation and insulin expression. Mol. Cell. Biol. 2013, 33:319-327.
29. Matera A.G., Wang Z. A day in the life of the spliceosome. Nat. Rev. Mol. Cell Biol. 2014, 15:108-121.
30. Matlin A.J., Clark F., Smith C.W. Understanding alternative splicing: towards a cellular code. Nat. Rev. Mol. Cell Biol. 2005, 6:386-398.
31. Mercatante D.R., Bortner C.D., Cidlowski J.A., Kole R. Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. analysis of apoptosis and cell death. J. Biol. Chem. 2001, 276:16411-16417.
32. Oltean S., Bates D.O. Hallmarks of alternative splicing in cancer. Oncogene 2013, Published online December 16, 2013. 10.1038/onc.2013.533.
33. Sakamuro D., Elliott K.J., Wechsler-Reya R., Prendergast G.C. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat. Genet. 1996, 14:69-77.
34. Schwerk C., Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol. Cell 2005, 19:1-13.
35. Selamat S.A., Chung B.S., Girard L., Zhang W., Zhang Y., Campan M., Siegmund K.D., Koss M.N., Hagen J.A., Lam W.L., et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 2012, 22:1197-1211.
36. Shkreta L., Froehlich U., Paquet E.R., Toutant J., Elela S.A., Chabot B. Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes. Mol. Cancer Ther. 2008, 7:1398-1409.
37. Shkreta L., Bell B., Revil T., Venables J.P., Prinos P., Elela S.A., Chabot B. Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing. Cancer Treat. Res. 2013, 158:41-94.
38. Uniacke J., Holterman C.E., Lachance G., Franovic A., Jacob M.D., Fabian M.R., Payette J., Holcik M., Pause A., Lee S. An oxygen-regulated switch in the protein synthesis machinery. Nature 2012, 486:126-129.
39. Venables J.P. Unbalanced alternative splicing and its significance in cancer. BioEssays 2006, 28:378-386.
40. Venables J.P., Klinck R., Bramard A., Inkel L., Dufresne-Martin G., Koh C., Gervais-Bird J., Lapointe E., Froehlich U., Durand M., et al. Identification of alternative splicing markers for breast cancer. Cancer Res. 2008, 68:9525-9531.
41. Villemaire J., Dion I., Elela S.A., Chabot B. Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides. J. Biol. Chem. 2003, 278:50031-50039.
42. Wang Z., Burge C.B. Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. RNA 2008, 14:802-813.
43. Wang Y., Cheong C.G., Hall T.M., Wang Z. Engineering splicing factors with designed specificities. Nat. Methods 2009, 6:825-830.
44. Wang Y., Ma M., Xiao X., Wang Z. Intronic splicing enhancers, cognate splicing factors and context-dependent regulation rules. Nat. Struct. Mol. Biol. 2012, 19:1044-1052.
45. Wang Y., Xiao X., Zhang J., Choudhury R., Robertson A., Li K., Ma M., Burge C.B., Wang Z. A complex network of factors with overlapping affinities represses splicing through intronic elements. Nat. Struct. Mol. Biol. 2013, 20:36-45.
46. Warzecha C.C., Jiang P., Amirikian K., Dittmar K.A., Lu H., Shen S., Guo W., Xing Y., Carstens R.P. An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J. 2010, 29:3286-3300.
47. Williams K., Motiani K., Giridhar P.V., Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp. Biol. Med. (Maywood) 2013, 238:324-338.
48. Yae T., Tsuchihashi K., Ishimoto T., Motohara T., Yoshikawa M., Yoshida G.J., Wada T., Masuko T., Mogushi K., Tanaka H., et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat. Commun. 2012, 3:883.
49. Zhu H., Guo W., Zhang L., Davis J.J., Teraishi F., Wu S., Cao X., Daniel J., Smythe W.R., Fang B. Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol. Cancer Ther. 2005, 4:451-456.